TITLE:
A Study to Evaluate the Safety of Escalating Doses of Ocrelizumab in Subjects With Rheumatoid Arthritis

CONDITION:
Rheumatoid Arthritis

INTERVENTION:
ocrelizumab

SUMMARY:

      This is a randomized, placebo-controlled, multicenter, blinded Phase I/II, investigator and
      subject-blinded study of the safety of escalating doses of ocrelizumab in combination with
      MTX in subjects with moderate to severe RA
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to 80 Years
Criteria:

        Inclusion Criteria:

          -  Ability and willingness to provide written informed consent and to comply with the
             requirements of the protocol

          -  Diagnosis of RA for at least 6 months according to the revised 1987 ACR criteria for
             the classification of RA

          -  Positive serum RF

          -  Current treatment for RA on an outpatient basis

          -  Contact your local site that is listed for more inclusion criteria

        Exclusion Criteria:

          -  Bone or joint surgery (including joint fusion) within 8 weeks prior to screening or
             joint surgery planned within 24 weeks after randomization

          -  Rheumatic autoimmune disease other than RA or significant systemic involvement
             secondary to RA (e.g., vasculitis, pulmonary fibrosis, or Feltys syndrome)

          -  Functional Class IV as defined by the ACR classification of functional status in RA

          -  History of or current inflammatory joint disease other than RA (e.g., gout, reactive
             arthritis, psoriatic arthritis, seronegative spondyloarthropathy, Lyme disease) or
             other systemic rheumatic disorders (e.g., systemic lupus erythematosus, inflammatory
             bowel disease, scleroderma, inflammatory myopathy, overlap syndrome)

          -  Contact your local site that is listed for more exclusion criteria
      
